Healthcare Services

Pancreatic Cancer Diagnostic Market Growth Expected to Reach $6.95 Billion by 2030 with 9% CAGR

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Pancreatic Cancer Diagnostic Market In 2026 And What Value Is Projected For 2030?

The pancreatic cancer diagnostic market has experienced substantial growth in its size over recent years. It is projected to expand from $4.54 billion in 2025 to $4.93 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.6%. Historically, this expansion can be linked to several factors, including the restricted availability of advanced diagnostic instruments, a reliance on conventional imaging and biopsy techniques, low rates of early detection, fragmented diagnostic service provision, and a diagnostic model primarily centered around hospitals.

The pancreatic cancer diagnostic market is anticipated to experience substantial expansion in the coming years. It is set to reach $6.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.0%. This projected growth during the forecast period is fueled by the growing utilization of genomic and biomarker-driven tests, the integration of AI and machine learning into diagnostic processes, the development of minimally invasive liquid biopsy techniques, the broadening of diagnostic offerings in hospitals and cancer centers, and an increase in combined laboratory and consulting services. Key trends anticipated for this period encompass the uptake of sophisticated genomic testing for pancreatic cancer, the incorporation of AI-driven diagnostic imaging, an increase in liquid biopsy and other less invasive testing methods, advances in precision medicine diagnostics, and the broadening of services provided by hospitals and diagnostic centers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11981&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Pancreatic Cancer Diagnostic Market?

The rising healthcare expenditure is driving the expansion of the pancreatic cancer diagnostic market. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a particular region, country, or organization. This spending directs resources to pancreatic cancer diagnostics to facilitate early detection, accurate staging, and timely intervention, aiming to improve patient outcomes and survival rates. For instance, in November 2023, the Canadian Institute for Health Information, a Canada-based institute for health information, projected total health spending in Canada to reach $344 billion in 2023, equivalent to $8,740 per person. This represents a 2.8% increase over the prior year, compared to only a 1.5% growth in health spending in 2022, indicating a notable resurgence in healthcare investment. Therefore, an increase in healthcare spending is propelling the growth of the pancreatic cancer diagnostic market.

What Are The Key Segments Of The Pancreatic Cancer Diagnostic Market?

The pancreatic cancer diagnostic market covered in this report is segmented –

1) By Product: Instruments, Consumables, Services

2) By Treatment: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy

3) By Cancer Type: Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Colloid Carcinoma, Endocrine

4) By Test Type: Imaging Test, Biopsy, Blood Test, Genomic Test, Other Test Types

5) By End-User: Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Instruments: Imaging Systems, Biopsy Devices, Endoscopy Equipment

2) By Consumables: Reagents, Biopsy Needles, Assay Kits

3) By Services: Diagnostic Testing Services, Laboratory Services, Consulting Services

How Are Trends Shaping The Direction Of The Pancreatic Cancer Diagnostic Market?

Leading firms within the pancreatic cancer diagnostic market are concentrating on creating novel solutions, including biomarker-based diagnostic kits, to address the increasing need for early identification, enhanced diagnostic precision, and superior patient survival rates. These biomarker-driven diagnostics work by detecting tumor-related proteins or genetic indicators in blood or tissue samples, providing a more precise and targeted method compared to traditional imaging-based diagnoses, which frequently identify pancreatic cancer only in its later stages. As an example, in March 2023, Prestige Biopharma Limited, a biopharmaceutical firm headquartered in Singapore, introduced its pioneering PAUF-detecting diagnostic kit, a potent tool designed for the prompt discovery of pancreatic cancer. PAUF (Pancreatic Adenocarcinoma Upregulated Factor) serves as a distinct tumor-specific biomarker linked to early metastasis and is overexpressed in approximately 80% of pancreatic cancer instances. This cutting-edge diagnostic method demonstrates significant sensitivity and specificity in identifying PAUF. Initial research indicated that the concentration of PAUF in the blood plasma of individuals with pancreatic cancer is nearly 1.9 times greater than in healthy people, according to data from Prestige Biopharma’s IDC (Innovative Discovery Center).

Who Are The Leading Companies Operating In The Pancreatic Cancer Diagnostic Market?

Major companies operating in the pancreatic cancer diagnostic market are Hitachi Medical Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Biological Dynamics Inc., Berg LLC, Abcodia Ltd., Acobiom, Amplified Sciences LLC, Avant Diagnostics Inc., Axim Biotechnologies Inc., Alaunus Biosciences Inc., Advanced Marker Discovery SL, Anixa Diagnostics Corporation

Read the full pancreatic cancer diagnostic market report here:

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

What Are The Leading Geographic Regions In The Pancreatic Cancer Diagnostic Market?

North America was the largest region in the pancreatic cancer diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pancreatic Cancer Diagnostic Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11981&type=smp

Browse Through More Reports Similar to the Global Pancreatic Cancer Diagnostic Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Diagnostic Global Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Acute Pancreatitis Global Market Report

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795